

University of Dundee

A randomised phase III study of 72 hour infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3)

Shamash, J.; Sarker, S. J.; Huddart, R.; Harland, S.; Joffe, J. K.; Mazhar, D.

Published in:
Annals of Oncology

DOI:
[10.1093/annonc/mdx071](https://doi.org/10.1093/annonc/mdx071)

Publication date:
2017

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Shamash, J., Sarker, S. J., Huddart, R., Harland, S., Joffe, J. K., Mazhar, D., Birtle, A., White, J., Chowdhury, K., Wilson, P., Marshall, M. R., & Vinnicombe, S. (2017). A randomised phase III study of 72 hour infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). *Annals of Oncology*, 28(6), 1333-1338.
<https://doi.org/10.1093/annonc/mdx071>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Article type: Original Article

A randomised phase III study of 72 hour infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3)

J. Shamash¹, S.-J. Sarker¹, R. Huddart², S. Harland³, J.K. Joffe⁴, D. Mazhar⁵, A. Birtle⁶, J. White⁷, K. Chowdhury¹, P. Wilson¹, M. R. Marshall¹, and S. Vinnicombe⁸

1. Centre for Experimental Cancer Medicine, Barts Cancer Institute, QMUL, UK.
2. Institute of Cancer Research, London, UK.
3. University College London Hospitals, Department of Oncology, London, UK.
4. Huddersfield Royal Infirmary, UK.
5. Addenbrookes' Hospital, Cambridge, UK.
6. Lancashire Teaching Hospitals, UK.
7. Beatson West of Scotland Cancer Centre, UK.
8. School of Medicine, University of Dundee, UK.

Corresponding address:

Dr Jonathan Shamash, MD FRCP
Consultant Medical Oncologist
Barts Cancer Institute, Bart's Health NHS Trust
Queen Mary's School of Medicine and Dentistry
LONDON EC1M 6BQ
E-mail: Jonathan.Shamash@bartshealth.nhs.uk

This is a pre-copyedited, author-produced version of an article accepted for publication in *Annals of Oncology* following peer review. The version of record J. Shamash, S.-J. Sarker, R. Huddart, S. Harland, J.K. Joffe, D. Mazhar, A. Birtle, J. White, K. Chowdhury, P. Wilson, M. R. Marshall, S. Vinnicombe; A randomised phase III study of 72 hour infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). *Ann Oncol* 2017; 28(7):1-10 is available online at:

<https://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx071/3038395/A-randomised-phase-III-study-of-72hour-infusional?rss=1>

1 **Abstract**

2 **Background:** Bleomycin is an integral part of combination chemotherapy in germ cell tumours.
3 Pulmonary toxicity often necessitates drug cessation and death occurs in 1-2% of patients. A
4 continuous infusion of bleomycin might reduce lung toxicity when compared to the
5 conventional weekly boluses given as part of standard BEP chemotherapy.

6 **Patients and Methods:** A phase 3 randomised trial was conducted. Two hundred and twelve
7 men with IGCCCG good prognosis metastatic germ cell tumours were randomized in a 1:1
8 fashion. They were stratified for age, smoking history and renal function. Patients received
9 either conventional BEP with weekly bleomycin (30000 units /week IV bolus) or as a 90000 unit
10 infusion on day 1 over 72 hours. The primary endpoint was CT assessed lung toxicity, secondary
11 endpoints included PFS, changes in lung function testing and quality of life. Repeated measures
12 mixed effects model was used to analyse the data.

13 **Results:** CT assessed lung toxicity for the infusional and conventional arm patients were respectively
14 80% versus 62% at the end of treatment and 54% versus 51% at one year post treatment. There was no
15 significant difference between the two arms for CT assessed lung toxicity (estimated regression
16 coefficient (difference) =1.4, $P=0.9$, 95% CI:-0.36, 3.16). Older patients had higher toxicity
17 (coefficient=4.81, 95% CI: 3.04, 6.58). Lung toxicity increased after 1 cycle and peaked at end of
18 treatment ($P\leq 0.002$) and then declined. Lung function testing failed to show any differences
19 between the two arms, and did not predict for subsequent lung damage. The median follow-up
20 was 2.5 years. Two-year PFS rate (infusional arm= 93% versus conventional arm=94%; hazard
21 ratio =0.91, 95% CI: 0.33, 2.52) was not significantly different. Cough ($P=0.002$) but not
22 shortness of breath ($P\geq 0.09$) was associated with bleomycin toxicity.

23 **Conclusions:** Infusional bleomycin has no advantage over standard administration. It supports
24 abandoning routine pulmonary function testing, instead the presence of cough should be
25 sought and the early use of CT scanning of the chest to evaluate potential lung toxicity is
26 preferred.

27 **Keywords:** germ cell tumour, bleomycin, infusion, lung

28 **Introduction**

29 Most patients with IGCCCG good prognosis metastatic germ cell tumours are cured with 3
30 cycles of cisplatin, etoposide and bleomycin (BEP). Randomised studies have confirmed
31 cisplatin 100mg/m², etoposide 500mg/m² and bleomycin 90,000 units per cycle to be optimal
32 [1, 2]. The cisplatin and etoposide may be given over 3 or 5 days [2] and reductions in the
33 dosage of bleomycin or etoposide are associated with poorer overall survival [1, 3]. Bleomycin
34 has long been known to cause unpredictable and occasionally fatal lung toxicity. Prior poor lung
35 function, a smoking history, and impaired renal function may predispose to an increased
36 likelihood of toxicity [4]. Retrospective reports suggest that the damage caused by bleomycin
37 be related to the peak levels of the drug which may be avoided by giving the drug as a
38 continuous infusion [5]. In vivo experiments in animal models support this hypothesis [6].
39 In a patient group with a good outcome, optimisation of bleomycin may be expected to
40 improve efficacy and reduce toxicity. As the value of pulmonary function testing in this setting
41 has been controversial [7] we wished to see whether pre- treatment pulmonary function
42 testing could identify an at-risk population for development of lung toxicity and whether
43 changes during treatment correlated with the development of CT scan changes. We also wished
44 to determine whether any symptoms associated with the development of bleomycin induced
45 lung injury e.g. shortness of breath, cough, and chest discomfort correlated with CT changes.
46 We therefore performed a randomised trial.

47

48 **Patients and Methods**

49 Eligible patients were males over 16years old with IGCCCG good prognosis disease (testicular
50 germ cell tumours with metastases but no non-pulmonary visceral sites with tumour markers
51 not exceeding the following AFP 1000ng/ml, hCG, 5000 iU/ml, LDH 1.5x the upper limit of
52 normal).

53 All patients were staged using CT scanning. The pulmonary parenchyma was assessed using
54 conventional lung settings rather than dedicated high resolution CT of the chest. Patients were
55 required to have adequate renal function (calculated or measured glomerular filtration rate of >
56 50ml/min). Patients were randomised to receive 3 cycles of 3 day BEP (cisplatin 50mg/m² on
57 day 1 and 2, etoposide 166mg/m² day 1, 2 and 3) and either conventional bleomycin 30,000
58 units per week on days 1, 8 and 15 as a 30min intravenous infusion (conventional arm) or a
59 protracted infusion (90,000 units as a continuous intravenous infusion over 3 days on days 1, 2
60 and 3 of each cycle (infusional arm). Routine use of growth factors was not permitted.. A
61 conventional chest CT, quality of life, and pulmonary function tests were performed
62 immediately prior to the second cycle, at the end of treatment (9 weeks after chemotherapy
63 started), 1 year and 2 years after treatment.

64 Quality of life assessments used the EORTC QLQC-30 questionnaire with the addition of LC 17
65 (originally developed for lung cancer, it was used to look for specific symptoms attributable to
66 lung toxicity) [8].

67 The primary end point of the study was the development of CT assessed lung toxicity
68 attributable to bleomycin. The validated endpoint CT changes were selected, as they, rather
69 than changes in lung function correlate best with long term pulmonary damage [4, 9, 10]. The

70 secondary endpoints were progression-free survival, overall survival, changes in pulmonary
71 function testing, and quality of life. Pulmonary function tests included an assessment of FEV1,
72 FVC, TICO and KCO.

73 Patients were required to give written informed consent. The trial had formal ethical approval
74 (trial reg MREC 3/3/029).

75

76 CT review

77 All the CT scans were anonymised, the reporting radiologist was blinded to treatment allocation
78 and all scans viewed by a single radiologist. The scans were reported as follows. As this was a
79 multicentre trial, scan acquisition varied according to institution, but in all cases, slice thickness
80 was no more than 2.5mm. Where dedicated lungs settings were not provided, a standard edge
81 algorithm was applied. Each lung field was split into an anterior and posterior section (4 in all-
82 right anterior, right posterior, left anterior and left posterior). The degree of CT assessed lung
83 toxicity was graded between 0-3. Grade 1 changes represented subtle fine sub-pleural linear
84 opacity, grade 2 changes – more pronounced than grade 1 but with no coalescence or
85 consolidation. Grade 3 represented more diffuse changes with coalescence [11]. The number
86 or total sections with subpleural changes for each scan examined was noted allowing a
87 percentage of sections with involved changes to be derived, as well as the proportion of grade
88 2 and 3 changes. The results were summarised in the following format – the percentage of
89 sections showing any damage, the number of sections showing individually grade1, 2 or 3
90 damage. This was carried out at baseline, day 21, end of treatment and 1 and 2 years post

91 treatment. In some patients changes were present prior to chemotherapy – these were termed
92 baseline changes, their subsequent presence post chemotherapy were therefore not
93 attributable to bleomycin.

94

95 **Statistics**

96 A previous retrospective review of the toxicity encountered when bleomycin was administered
97 as a continuous infusion had suggested a substantial reduction in bleomycin induced changes (a
98 difference of 44%). It was felt to be worthwhile even if the reduction in toxicity were around
99 15%. Therefore a reduction in toxicity from 27% (expected) to 11% required a total of 210
100 patients at the 5% level of significance with 80% power based on a 2-sided test.

101 Randomisation, following 1:1 allocation, was stratified for smoking (smoker vs non-smoker),
102 renal dysfunction ($> 80\text{ml/min}$ or $\leq 80\text{ml/min}$ as calculated by Cockcroft and Gault) and age (<30
103 vs ≥ 30 years) as all these factors have been associated with an increased risk of bleomycin
104 induced lung toxicity [4, 12].

105 To determine the statistical significance of the association between categorical and continuous
106 outcome variables, the Chi-square and Independent samples T-test were used as appropriate.
107 Repeated measures mixed effects models were used to model CT proven lung toxicity as a
108 function of the predictor variables accounting for both fixed effects (stratification factors) and
109 random effect(patient ID). Nonparametric testing for trend was carried out to observe for
110 trends in toxicity grading with time. Pearson's correlation coefficients were used to assess

111 correlation between lung function variables and lung toxicity at each time point and then linear
112 regression was used for prediction. Association between quality of life (symptoms) and change
113 of lung toxicity (end of treatment - baseline) was studied using two-sample t-test.

114

115 **Results**

116 Two hundred and twelve patients from 13 sites were randomised (105 in the infusional arm and
117 107 in the conventional arm), see CONSORT diagram in S1. Table 1 confirms the validity of
118 randomization with the two groups well balanced in terms of baseline characteristics. Thirty-
119 five percent of patients were smokers, 5% had an estimated GFR of < 80ml/min and 53% were
120 over the age of 30. The median follow-up was 2.3 years.

121 The proportion of patients with CT detected lung toxicity (any, grade ≥ 2 , grade 3) respectively increased
122 from baseline (12.2%, 0%, 0%) to day 21 (29.5%, 2%, 0%) and end of treatment (70.5%, 34.5%, 5.1%) but
123 improved at 1 year post treatment (52.4%, 4.2%, 0.6%) and 2 years post treatment (47.9%, 2.6%, 0.9%).
124 There was a significant trend for increasing CT defined toxicity after 1 cycle, which peaked at
125 the end of treatment ($P \leq 0.002$).

126 Thirty percent of patients (n=37) had CT assessed grade 1 toxicity by day 21 and 35% of them
127 increased to grade ≥ 2 toxicity by the end of the treatment. Eighty four (68%) patients showed no
128 evidence of lung toxicity at day 21 but 27% of them went on to develop grade ≥ 2 lung toxicity at
129 the end of treatment.

130 Those patients with smaller body surface areas (< median) did not have significantly higher
131 toxicity (small BSA: 38% vs higher BSA: 34%, $P=0.18$) at the end of treatment despite the fact
132 that bleomycin dosing was fixed independently of body size.

133

134 **Treatment comparison:**

135 Table 2 shows that toxicity in the infusional arm was generally higher than the conventional arm
136 and it was significantly higher at the end of treatment (80% vs. 62%, $P=0.01$).

137 Repeated measures mixed effects analysis, Table 3, shows that there was no significant
138 difference (CI includes zero) in percentage of grade ≥ 1 toxicity between the two arms
139 (estimated coefficient=1.4; 95% CI: -0.36, 3.16). It confirms that a significantly higher level of
140 grade ≥ 2 toxicity in the infusion arm (0.92; 0.22, 1.62) mainly at the end of treatment. Baseline
141 toxicity was significant (1 unit increase gave the percentage of grade ≥ 2 toxicity decrease by a
142 factor of 0.16). Of the stratified factors only age was statistically significant. Patients older than
143 30 had on an average 4.8 percentage point higher grade ≥ 1 toxicity but 0.84 percentage point
144 lower grade ≥ 2 toxicity. Smoking was not associated with baseline damage ($P = 0.5$), nor was it
145 related to the severity and frequency of subsequent bleomycin toxicity (Table 3). The total
146 doses of bleomycin was the same in both groups.

147 Two-year PFS rate (infusional arm= 92.5% versus conventional arm=94.1%; hazard ratio =0.91,
148 95% CI 0.33 to 2.52) was not significantly different.

149

150 **Lung function and CT assessed toxicity:**

151 There was no relationship between pre-existing lung function and subsequent CT assessed
152 toxicity (see Table 4). Pulmonary function declined during treatment and then recovered 1 year
153 post therapy (Figure S2). Table 4 shows that decreased lung function was weakly correlated ($r \approx$
154 0.30) with increased toxicity only at the end of treatment ($P < 0.05$), especially based on DLCO
155 (kco). Pre-treatment lung function did not predict subsequent development of pulmonary
156 toxicity (all CIs include 0); (Table S1).

157

158 **Quality of Life (see Table 5)**

159 The quality of life data showed that the development of a dry cough ($P = 0.002$) rather than
160 shortness of breath ($P \geq 0.09$) or chest tightness ($P = 0.18$) was the only symptom significantly
161 associated with the development of CT assessed lung toxicity. Shortness of breath showed a
162 positive association with the development of CT assessed lung toxicity but was not significant
163 ($P = 0.09$).

164

165 **Discussion**

166 A continuous infusion of of bleomycin over 72 hours was unable to reduce the likelihood of
167 developing pulmonary toxicity compared to conventional administration. There was
168 significantly higher level of grade ≥ 2 toxicity in patients in the infusion arm, refuting the above

169 hypothesis. Nevertheless this study has expanded our knowledge as to the timing of
170 development of lung toxicity and the natural history of its resolution.

171 There was no suggestion that efficacy was increased by this approach despite animal models
172 suggesting otherwise [6]. Supporting this conclusion, an in vivo study based on hetero-
173 transplanted testicular cancer cell lines found no significant difference in anti-tumour activity or
174 toxicity on histological examination between continuous or bolus application of bleomycin
175 where the same cumulative doses were compared [11].

176 Pulmonary toxicity from bleomycin may be related to peak levels and one weakness of this
177 study was failure to measure these – it is possible that the infusion produced higher levels than
178 anticipated and that a more prolonged infusion might have reduced toxicity.

179 This was a pragmatic study – high resolution CT scanning was not used to assess pulmonary
180 toxicity on the basis that we were not looking for a test to be more sensitive but wanted to
181 assess clinically more relevant changes. It could be argued that the varying scan protocols and
182 acquisition parameters could have obscured significant differences, but the within-institution
183 randomisation ensured that such bias was minimised. Similarly, subtle changes attributable to
184 bleomycin could have been obscured by normal hypostatic changes, since prone scans were not
185 routinely acquired, but this would be expected to affect subjects in both arms equally and the
186 fact that serial scans were obtained in each patient minimised the likelihood of changes being
187 missed or misinterpreted. Whilst intra-observer variability was controlled for by – re-reporting
188 of blinded scans - a weakness of having only one radiologist reporting all the scans was that the
189 potential role of inter-observational error could not be assessed.

190 The finding of changes, progressing until the end of treatment and then regressing, offers an
191 opportunity for using early changes as a warning for more severe damage if bleomycin is
192 continued. A recent study confirmed a similar pattern of change in lung damage as seen in TE3
193 with most of the changes in lung function reversing within 1 year of treatment[13]. They
194 however used changes in diffusion capacity to reduce or omit bleomycin which they felt did
195 not reduce survival. Their study differed in that it included poor and intermediate prognosis
196 patients who would have received 4 cycles of bleomycin. This may be important as many of the
197 factors thought to be associated with subsequent pulmonary toxicity were not borne out in our
198 study. Neither baseline pulmonary, nor smoking history, nor renal function predicted toxicity,
199 however In the case of renal function, most (92%) had an estimated glomerular filtration rate
200 of > 80ml/ min, so although no association was noted it might simply suggest that only
201 significantly impaired renal function increased bleomycin toxicity.

202

203 Bleomycin lung toxicity remains unpredictable and can be fatal which can lead to dropping
204 bleomycin to avoid risk. For 3 cycles of cisplatin and etoposide the absence of bleomycin was
205 associated with a poorer survival [14]. It is unclear whether dropping bleomycin can be
206 compensated for by the addition of a 4th cycle of cisplatin and etoposide. One study –
207 underpowered to show a survival difference showed a 5% higher event rate in patients
208 randomized to 4 cycles of cisplatin and etoposide [15].

209

210 Pulmonary function testing was not useful to identify patients at risk of developing lung toxicity.
211 It was stipulated in the study that no reductions in bleomycin dosage for asymptomatic changes

212 in pulmonary function testing should be made. This is not the first time that the value of
213 pulmonary function testing has been questioned [16]. This argues for the abandonment of
214 routine pulmonary function testing, which may avoid patients having their bleomycin omitted.

215 In our study, early CT scanning after 1 cycle of treatment, rather than pulmonary function
216 testing or smoking history, was best able to identify patients at risk of subsequent lung toxicity.

217

218 The symptom assessment questionnaire showed that cough rather than shortness of breath
219 was the most important symptom to assess before administration of bleomycin and if this were
220 noted in the absence of another cause, an early CT of the chest might be performed prior to
221 further administration of bleomycin to establish if pulmonary toxicity had occurred.

222 The number of treatment failures in each arm (6%) was less than seen in previous randomised
223 studies in this population [1, 2] despite the fact that the median age group was higher (32
224 years) than in comparable studies. The low level of treatment delays and drug omissions may
225 have been responsible for this. It is important to point out that the overall prevalence of
226 bleomycin induced lung damage was relatively low due to the fact that the study only included
227 patients with good prognosis disease. In patients with more pulmonary disease where the total
228 doses of bleomycin would be greater, risks would likely be higher. In a review by Sullivan et al
229 [4] of patients treated, age, dose (> 300, 000 units) and renal dysfunction were associated with
230 increased risk of damage.

231

232 **Conclusions:**

233 Bleomycin induced lung damage in patients with good prognosis germ cell tumours occurs
234 independently of the method of delivery. The study supports the abandoning of routine
235 pulmonary function testing both to identify patients at risk or during treatment as a means of
236 detecting deterioration in pulmonary function. Instead, symptoms, especially cough, leading to
237 the early use of CT is preferred. A history of smoking may not be a reason to withhold
238 bleomycin. Whether these findings extend to patients with more advanced disease remains
239 undetermined.

240

241 **Acknowledgements**

242 We thank the following investigators: Dr J le Vay (Ipswich), Dr M Ostrowski (Norwich), Dr S
243 Nicholson (Southend), and Dr A Champion (Glan Clwyd). We also thank all participating patients
244 and the CRUK experimental cancer medicine centre for support. Funding for trial infrastructure
245 was provided by CRUK and the Orchid charity.

246

247 **References**

- 248 1. Toner GC, Stockler MR, Boyer MJ et al. Comparison of two standard chemotherapy regimens for
249 good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial
250 Group. Lancet 2001; 357: 739-745.
- 251 2. de Wit R, Roberts JT, Wilkinson PM et al. Equivalence of three or four cycles of bleomycin,
252 etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer:
253 a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary
254 Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19: 1629-1640.
- 255 3. Loehrer PJ, Sr., Johnson D, Elson P et al. Importance of bleomycin in favorable-prognosis
256 disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13: 470-
257 476.

- 258 4. O'Sullivan JM, Huddart RA, Norman AR et al. Predicting the risk of bleomycin lung toxicity in
259 patients with germ-cell tumours. *Ann Oncol* 2003; 14: 91-96.
- 260 5. Cooper KR, Hong WK. Prospective study of the pulmonary toxicity of continuously infused
261 bleomycin. *Cancer Treat Rep* 1981; 65: 419-425.
- 262 6. Sikic BI, Collins JM, Mimnaugh EG, Gram TE. Improved therapeutic index of bleomycin when
263 administered by continuous infusion in mice. *Cancer Treat Rep* 1978; 62: 2011-2017.
- 264 7. Sleijfer S, van der Mark TW, Schraffordt Koops H, Mulder NH. Decrease in pulmonary function
265 during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin
266 effect. *Br J Cancer* 1995; 71: 120-123.
- 267 8. EORTC QLQ-C30 Scoring Manual. In Third edition Edition. QL Coordinator, Quality of Life Unit,
268 EORTC Data Center, Avenue E Mounier 83-B11, 1200 Brussels, Belgium 2001.
- 269 9. Buchler T, Bomanji J, Lee SM. FDG-PET in bleomycin-induced pneumonitis following ABVD
270 chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease
271 activity. *Haematologica* 2007; 92: e120-121.
- 272 10. Taywade SK, Kumar R, Bhethanabhotla S, Bal C. Role of (18)F-FDG PET-CT in Monitoring the
273 Cyclophosphamide Induced Pulmonary Toxicity in Patients with Breast Cancer - 2 Case Reports. *Nucl*
274 *Med Mol Imaging* 2016; 50: 261-265.
- 275 11. Bokemeyer C, Ludwig E, Reile D et al. Antitumor-activity and toxicity of continuous-infusion
276 versus bolus administration of bleomycin in 2 heterotransplanted human testicular cancer cell-lines.
277 *Oncol Rep* 1995; 2: 161-165.
- 278 12. Hansen SW, Groth S, Sorensen PG et al. Enhanced pulmonary toxicity in smokers with germ-cell
279 cancer treated with cis-platinum, vinblastine and bleomycin: a long-term follow-up. *Eur J Cancer Clin*
280 *Oncol* 1989; 25: 733-736.
- 281 13. Lauritsen J, Kier MG, Bandak M et al. Pulmonary Function in Patients With Germ Cell Cancer
282 Treated With Bleomycin, Etoposide, and Cisplatin. *J Clin Oncol* 2016; 34: 1492-1499.
- 283 14. de Wit R, Stoter G, Kaye SB et al. Importance of bleomycin in combination chemotherapy for
284 good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research
285 and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. *J Clin Oncol* 1997; 15: 1837-
286 1843.
- 287 15. Culine S, Kerbrat P, Kramar A et al. Refining the optimal chemotherapy regimen for good-risk
288 metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the
289 French Federation of Cancer Centers (GETUG T93BP). *Ann Oncol* 2007; 18: 917-924.
- 290 16. Rimmer MJ, Dixon AK, Flower CD, Sikora K. Bleomycin lung: computed tomographic
291 observations. *Br J Radiol* 1985; 58: 1041-1045.

292 Appendix:

Figures and Tables

Supplementary Figure 1: Consort diagram showing study population

Supplementary Figure 2: Trend in toxicity based on lung function tests by arm

Table 1: Baseline characteristics of study patients

Table 2. Percentage of patients with various level of CT assessed lung toxicity

Table 3: Repeated measures mixed effects models of levels of lung toxicity

Table 4: Correlation between lung function and lung toxicity

Supplementary Table S1: Simple linear regression analysis results for association between pre-treatment lung function and end of treatment toxicity

Table 5: Association between symptoms and lung toxicity

Table 1. Baseline characteristics of study patients

Baseline characteristics	Infusional arm (N= 105)		Conventional (Bolus) arm (N= 107)	
	<i>n</i>	%	<i>n</i>	%
Baseline toxicity (mean (SD))*	0.89 (4.5)		0.78 (2.5)	
Age (years)				
<=30	49	46.7	51	47.7
>30	56	53.3	56	52.3
Age (years) (median (IQR))	31.5 (26.5, 36.0)		31.5 (24.8, 39.1)	
Follow-up (years) (median (IQR))	2.3 (1.9, 3.7)		2.3 (2.1, 3.5)	
Smoking status				
Non-smoker	67	63.8	71	66.4
Smoker	38	36.2	36	33.6
Creatinine clearance				
<=80 ml/min	7	6.7	4	3.7
>80 ml/min	98	93.3	103	96.3

* % of grade ≥ 1 toxicity at baseline (i.e. changes present prior to treatment)

Table 2. Percentage of patients with various level of CT assessed lung toxicity

	Baseline		<i>P</i>	Day 21		<i>P</i>	End of treatment		<i>P</i>	1-year		<i>p</i>	2-year		<i>P</i>
	IA ¹	CA ²		IA	CA		IA	CA		IA	CA		IA	CA	
Any grade	9.5	15.0	0.34	31.5	27.3	0.71	79.8	62.0	0.01	54.3	50.6	0.65	50.9	45.2	0.58
Grade ≥2	0	0	-	4.0	0	0.25	44.7	25.0	0.01	3.7	4.6	1.00	3.6	1.6	0.60
Grade 3	0	0	-	0	0	-	8.2	2.2	0.09	1.2	0	0.48	1.8	0	0.47

¹IA: Infusional Arm. ²CA: Conventional Arm.

Table 3. Repeated measures mixed effects models for levels of CT assessed lung toxicity

	% of Grade ≥1 toxicity		% of Grade ≥2 toxicity		% of Grade 3 toxicity	
	Estimated coefficient (Difference)	95% CI	Estimated coefficient (Difference)	95% CI	Estimated coefficient (Difference)	95% CI
Treatment						
Conventional arm	<i>ref</i>		<i>ref</i>		<i>ref</i>	
Infusional arm	1.4	-0.36, 3.16	0.92	0.22, 1.62	0.05	-0.11, 0.22
Baseline toxicity	0.67	0.40, 0.94	0.16	0.04, 0.28	0.002	-0.03, 0.03
Age (years)						
≤30	<i>ref</i>		<i>ref</i>		<i>ref</i>	
>30	4.81	3.04, 6.58	0.84	0.14, 1.55	0.14	-0.03, 0.30
Smoking status						
Non-smoker	<i>ref</i>		<i>ref</i>		<i>ref</i>	
Smoker	0.49	-1.36, 2.34	0.06	-0.68, 0.79	0.11	-0.06, 0.28
Creatinine clearance						
≤80 ml/min	<i>ref</i>		<i>ref</i>		<i>ref</i>	
>80 ml/min	-0.79	-5.26, 3.68	0.15	-1.58, 1.88	-0.03	-0.44, 0.38
CT assessed toxicity						
Day 21	<i>ref</i>		<i>ref</i>		<i>ref</i>	
End of treatment	7.28	5.50, 9.06	2.25	1.55, 2.96	0.17	-0.002, 0.33
1 year post treatment	2.18	0.38, 3.98	0.08	-0.63, 0.79	-0.01	-0.18, 0.16
2 year post treatment	2.14	0.14, 4.14	-		-	

Table 4. Correlation between lung function and lung toxicity

Lung function test		Grade ≥ 1 lung toxicity					
		Baseline		End of treatment		One year post treatment	
		<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>	<i>r</i>	<i>P</i>
Baseline	fvc	0.03	0.7	-0.03	0.7	-0.02	0.8
	fev1	0.01	0.9	-0.13	0.1	-0.09	0.3
	tlc	0.03	0.8	0.02	0.8	0.02	0.8
	tlco	-0.07	0.5	-0.08	0.3	-0.07	0.4
	kco	-0.07	0.4	-0.08	0.3	-0.05	0.5
End of treatment	fvc			-0.32	<0.001	-0.26	0.003
	fev1			-0.36	<0.001	-0.27	0.003
	tlc	-	-	-0.19	0.06	-0.22	0.03
	tlco			-0.35	<0.001	-0.26	0.004
	kco			-0.2	0.02	-0.09	0.34
One year post treatment	fvc					-0.17	0.11
	fev1					-0.17	0.11
	tlc	-	-	-	-	-0.07	0.6
	tlco					-0.21	0.04
	kco					-0.04	0.7


Supplementary Table S1. Simple linear regression analysis results for association between pre-treatment lung function and end of treatment toxicity

	End of treatment toxicity					
	% of Grade ≥ 1 toxicity		% of Grade ≥ 2 toxicity		% of Grade 3 toxicity	
Pre-treatment lung function	Regression coefficient	95% CI	Regression coefficient	95% CI	Regression coefficient	95% CI
Baseline fvc	-0.45	-3.08, 2.18	-0.62	-1.84, 0.61	-0.01	-0.16, 0.23
Baseline fev1	-2.58	-5.80, 0.63	-1.1	-2.61, 0.40	0.12	-0.18, 0.41
Baseline tlc	0.28	-2.14, 2.70	-0.17	-1.30, 0.95	-0.05	-0.31, 0.20
Baseline tlco	-0.61	-1.79, 0.58	-0.46	-1.02, 0.09	0.01	-0.10, 0.13
Baseline kco	-3.93	-11.94, 4.07	-1.74	-5.51, 2.03	0.02	-0.74, 0.78

Table 5. Association between symptoms and change of lung toxicity (end of treatment - baseline)

Symptoms	Mean Grade ≥ 1 % lung toxicity			Mean Grade ≥ 2 % lung toxicity		
	Better or no change compared to baseline	Worse	<i>P</i>	Better or no change	Worse	<i>P</i>
Cough	8.3	17.3	0.001	1.8	5.9	0.002
Cough up mucus	10.4	13.3	0.33	3.0	3.4	0.8
Cough up blood	-	-	-	-	-	-
Tightness in chest	10.7	12.2	0.6	2.6	4.5	0.18
SOB at rest	12.0	7.2	0.16	3.7	0.7	0.09
SOB on walking	11.1	11.4	0.9	3.2	2.9	0.8
SOB on climbing stairs	10.4	12.9	0.36	3.0	3.4	0.8

Supplementary Figure S1: Consort diagram showing study population



Supplementary Figure S2. Trend in toxicity based on lung function tests by arm

